216 related articles for article (PubMed ID: 38134115)
1. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
3. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
[TBL] [Abstract][Full Text] [Related]
5. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
[TBL] [Abstract][Full Text] [Related]
7. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
8. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
[TBL] [Abstract][Full Text] [Related]
10. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
12. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
J Immunother; 2020 Jan; 43(1):38-42. PubMed ID: 31567704
[TBL] [Abstract][Full Text] [Related]
14. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
15. A case of Empty Sella syndrome with adrenal insufficiency masked by prednisolone after administration of immune checkpoint inhibitors.
Iwamoto Y; Tatsumi F; Ohnishi M; Katakura Y; Kimura T; Shimoda M; Nakanishi S; Mune T; Kaneto H
Medicine (Baltimore); 2024 Mar; 103(10):e37204. PubMed ID: 38457550
[TBL] [Abstract][Full Text] [Related]
16. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
Yabuki S; Hirai H; Moriya C; Kusano Y; Hasegawa T
Front Endocrinol (Lausanne); 2024; 15():1407192. PubMed ID: 38841300
[TBL] [Abstract][Full Text] [Related]
17. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
18. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
Rai M; Go M
Cureus; 2020 Apr; 12(4):e7625. PubMed ID: 32399358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
